2022-501797-19-00招募中1 期
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 80
- 试验地点
- 10
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Armin Ehninger
Scientific
AvenCell Europe GmbH
研究点 (10)
Loading locations...
相似试验
尚未招募
1 期
CAR-T for Claudin18.2 Positive Solid TumorsNCT07266311Chengdu Ucello Biotechnology Co., Ltd.18
招募中
1 期
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic MalignanciesAcute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia RefractoryNCT05949125AvenCell Europe GmbH80
招募中
2 期
CARLA-M19 : “Prospective non-randomized phase I/II study investigating the safety of CD19 CAR-T cells in patients with refractory/relapsed AML (Acute Myeloïd Leukemia) expressing CD19.”2023-509212-29-01Centre Hospitalier Universitaire De Lille5
招募中
2 期
A clinical trial to learn about the effects of YTB323 in people with difficult to treat severe diffuse cutaneous systemic sclerosis (dcSSc)2023-510380-34-00Novartis Pharma AG72
招募中
不适用
To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCTNCT07280494Peking University People's Hospital18